<p>Summit Therapeutics（納斯達克股票代碼：SMMT - 獲取免費報告）在週六發佈給客户和投資者的研究報告中，被華爾街 Zen 的股票分析師從 “強烈賣出” 評級上調至 “賣出” 評級。</p>
<p>獲取 <strong>Summit Therapeutics</strong> 的提醒：</p>
<ul>
<li>為什麼華爾街支持這三隻反彈股票</li>
</ul>
<p>其他幾位股票研究分析師也對 SMMT 發佈了報告。Stifel Nicolaus 在 4 月 8 日（星期三）的一份研究報告中開始覆蓋 Summit Therapeutics 的股票。他們給予該股票 “買入” 評級，並設定目標價為 45.00 美元。Citizens Jmp 在 1 月 30 日（星期五）的一份研究報告中重新發布了 “市場表現優於大盤” 評級，並設定目標價為 40.00 美元。Jefferies Financial Group 在 3 月 16 日（星期一）的一份研究報告中將 Summit Therapeutics 的股票評級從 “買入” 下調至 “持有”，並將目標價從 42.00 美元下調至 15.00 美元。Citigroup 在 4 月 8 日（星期三）的一份研究報告中開始覆蓋 Summit Therapeutics 的股票。他們對該股票設定了 “買入” 評級。最後，Piper Sandler 在週五的一份研究報告中將 Summit Therapeutics 的目標價從 17.00 美元下調至 16.00 美元，並對該股票設定了 “中性” 評級。兩位股票研究分析師給予該股票 “強烈買入” 評級，八位給予 “買入” 評級，五位給予 “持有” 評級，二位給予 “賣出” 評級。根據 MarketBeat 的數據，該股票目前的共識評級為 “適度買入”，共識目標價為 28.17 美元。</p>
<p><strong>獲取我們關於 Summit Therapeutics 的最新研究報告</strong></p>
<h2>Summit Therapeutics 股票表現</h2>
<ul>
<li>MarketBeat 週報 – 11/4 - 11/8</li>
</ul>
<p>納斯達克：SMMT 週五開盤價為 16.11 美元。Summit Therapeutics 的年低為 13.83 美元，年高為 30.98 美元。該公司的市值為 125 億美元，市盈率為-11.11，貝塔值為-1.25。該公司的 50 日移動平均線為 18.43 美元，200 日移動平均線為 17.87 美元。</p>
<p>Summit Therapeutics（納斯達克：SMMT - 獲取免費報告）最後一次發佈財報是在 4 月 30 日（星期四）。該公司報告的每股收益（EPS）為（0.24）美元，超出市場共識預期的（0.27）美元，超出幅度為 0.03 美元。作為一個整體，股票研究分析師預測 Summit Therapeutics 在當前財政年度的每股收益將為-1.31 美元。</p>
<h2>機構資金流入和流出</h2>
<ul>
<li>Summit Therapeutics：他們的肺癌藥物是遊戲規則改變者嗎？</li>
</ul>
<p>對沖基金和其他機構投資者最近買入和賣出了該股票的股份。Crowley Wealth Management Inc.在第三季度將其在 Summit Therapeutics 的股份增加了 66.7%。Crowley Wealth Management Inc.現在擁有該公司 1,500 股股票，價值 31,000 美元，此前在上個季度又購買了 600 股。Ball &amp; Co Wealth Management Inc.在第一季度購買了 Summit Therapeutics 的新頭寸，價值約 28,000 美元。Kestra Advisory Services LLC 在第四季度購買了 Summit Therapeutics 的新頭寸，價值約 28,000 美元。Parallel Advisors LLC 在第三季度購買了 Summit Therapeutics 的新頭寸，價值約 39,000 美元。最後，T. Rowe Price Investment Management Inc.在第四季度將其在 Summit Therapeutics 的股份增加了 2,654.4%。T. Rowe Price Investment Management Inc.現在擁有該公司 1,873 股股票，價值 33,000 美元，此前在上個季度又購買了 1,805 股。4.61% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>關於 Summit Therapeutics</h2>
<p>（獲取免費報告）</p>
<p>Summit Therapeutics plc 是一家臨牀階段的生物技術公司，致力於發現和開發針對嚴重和危及生命疾病的精準藥物。該公司採用針對性的藥物設計方法，專注於與現有療法不同的新機制。</p>
<p>Summit 的主要資產，ridinilazole（前稱 SMT19969），正在開發用於治療艱難梭狀芽孢桿菌感染，並已獲得美國的快速通道和合格感染性疾病產品的認證。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票，而不是 Summit Therapeutics</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U01NVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U01NVA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Summit Therapeutics 嗎？</h2>
<p>在你考慮 Summit Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Summit Therapeutics 並不在名單上。</p>
<p>雖然 Summit Therapeutics 目前在分析師中獲得 “適度買入” 評級，但頂級分析師認為這五隻股票更值得投資。</p>
<p>在這裏查看這五隻股票</p>

Summit治療

<p>華爾街禪將 Summit Therapeutics（NASDAQ:SMMT）的評級從 “強烈賣出” 上調至 “賣出”。其他分析師的意見各不相同，Stifel Nicolaus 給予 “買入” 評級，目標價為 45 美元，而 Jefferies 則將其評級下調至 “持有”，目標價為 15 美元。目前，該股票的共識評級為 “適度買入”，目標價為 28.17 美元。Summit Therapeutics 報告的季度每股收益為（0.24 美元），超出預期。該公司專注於針對嚴重疾病的精準醫療，其主要資產針對艱難梭狀芽胞桿菌感染</p>

<p>Summit Therapeutics (NASDAQ:SMMT - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a &#34;strong sell&#34; rating to a &#34;sell&#34; rating in a research report issued to clients and investors on Saturday.</p>
<div class="lb-trans"><p>Summit Therapeutics（納斯達克股票代碼：SMMT - 獲取免費報告）在週六發佈給客户和投資者的研究報告中，被華爾街 Zen 的股票分析師從 “強烈賣出” 評級上調至 “賣出” 評級。</p>
</div><p>Get <strong>Summit Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Summit Therapeutics</strong> 的提醒：</p>
</div><ul>
<li>Why Wall Street Is Backing These 3 Comeback Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>為什麼華爾街支持這三隻反彈股票</li>
</ul>
</div><p>Several other equities research analysts have also issued reports on SMMT. Stifel Nicolaus began coverage on shares of Summit Therapeutics in a research note on Wednesday, April 8th. They set a &#34;buy&#34; rating and a $45.00 target price on the stock. Citizens Jmp reissued a &#34;market outperform&#34; rating and set a $40.00 target price on shares of Summit Therapeutics in a research note on Friday, January 30th. Jefferies Financial Group lowered shares of Summit Therapeutics from a &#34;buy&#34; rating to a &#34;hold&#34; rating and lowered their target price for the stock from $42.00 to $15.00 in a research note on Monday, March 16th. Citigroup began coverage on shares of Summit Therapeutics in a research note on Wednesday, April 8th. They set a &#34;buy&#34; rating on the stock. Finally, Piper Sandler lowered their target price on shares of Summit Therapeutics from $17.00 to $16.00 and set a &#34;neutral&#34; rating on the stock in a research note on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $28.17.</p>
<div class="lb-trans"><p>其他幾位股票研究分析師也對 SMMT 發佈了報告。Stifel Nicolaus 在 4 月 8 日（星期三）的一份研究報告中開始覆蓋 Summit Therapeutics 的股票。他們給予該股票 “買入” 評級，並設定目標價為 45.00 美元。Citizens Jmp 在 1 月 30 日（星期五）的一份研究報告中重新發布了 “市場表現優於大盤” 評級，並設定目標價為 40.00 美元。Jefferies Financial Group 在 3 月 16 日（星期一）的一份研究報告中將 Summit Therapeutics 的股票評級從 “買入” 下調至 “持有”，並將目標價從 42.00 美元下調至 15.00 美元。Citigroup 在 4 月 8 日（星期三）的一份研究報告中開始覆蓋 Summit Therapeutics 的股票。他們對該股票設定了 “買入” 評級。最後，Piper Sandler 在週五的一份研究報告中將 Summit Therapeutics 的目標價從 17.00 美元下調至 16.00 美元，並對該股票設定了 “中性” 評級。兩位股票研究分析師給予該股票 “強烈買入” 評級，八位給予 “買入” 評級，五位給予 “持有” 評級，二位給予 “賣出” 評級。根據 MarketBeat 的數據，該股票目前的共識評級為 “適度買入”，共識目標價為 28.17 美元。</p>
</div><p><strong>Get Our Latest Research Report on Summit Therapeutics</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 Summit Therapeutics 的最新研究報告</strong></p>
</div><h2>Summit Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Summit Therapeutics 股票表現</h2>
</div><ul>
<li>MarketBeat Week in Review – 11/4 - 11/8</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 週報 – 11/4 - 11/8</li>
</ul>
</div><p>NASDAQ:SMMT opened at $16.11 on Friday. Summit Therapeutics has a one year low of $13.83 and a one year high of $30.98. The firm has a market cap of $12.50 billion, a price-to-earnings ratio of -11.11 and a beta of -1.25. The firm's fifty day moving average is $18.43 and its two-hundred day moving average is $17.87.</p>
<div class="lb-trans"><p>納斯達克：SMMT 週五開盤價為 16.11 美元。Summit Therapeutics 的年低為 13.83 美元，年高為 30.98 美元。該公司的市值為 125 億美元，市盈率為-11.11，貝塔值為-1.25。該公司的 50 日移動平均線為 18.43 美元，200 日移動平均線為 17.87 美元。</p>
</div><p>Summit Therapeutics (NASDAQ:SMMT - Get Free Report) last posted its earnings results on Thursday, April 30th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.03. As a group, equities research analysts predict that Summit Therapeutics will post -1.31 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Summit Therapeutics（納斯達克：SMMT - 獲取免費報告）最後一次發佈財報是在 4 月 30 日（星期四）。該公司報告的每股收益（EPS）為（0.24）美元，超出市場共識預期的（0.27）美元，超出幅度為 0.03 美元。作為一個整體，股票研究分析師預測 Summit Therapeutics 在當前財政年度的每股收益將為-1.31 美元。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><ul>
<li>Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?</li>
</ul>
<div class="lb-trans"><ul>
<li>Summit Therapeutics：他們的肺癌藥物是遊戲規則改變者嗎？</li>
</ul>
</div><p>Hedge funds and other institutional investors have recently bought and sold shares of the stock. Crowley Wealth Management Inc. lifted its stake in Summit Therapeutics by 66.7% in the 3rd quarter. Crowley Wealth Management Inc. now owns 1,500 shares of the company's stock valued at $31,000 after buying an additional 600 shares in the last quarter. Ball &amp; Co Wealth Management Inc. purchased a new position in Summit Therapeutics in the 1st quarter valued at about $28,000. Kestra Advisory Services LLC purchased a new position in Summit Therapeutics in the 4th quarter valued at about $28,000. Parallel Advisors LLC purchased a new position in Summit Therapeutics in the 3rd quarter valued at about $39,000. Finally, T. Rowe Price Investment Management Inc. lifted its stake in Summit Therapeutics by 2,654.4% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,873 shares of the company's stock valued at $33,000 after buying an additional 1,805 shares in the last quarter. 4.61% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>對沖基金和其他機構投資者最近買入和賣出了該股票的股份。Crowley Wealth Management Inc.在第三季度將其在 Summit Therapeutics 的股份增加了 66.7%。Crowley Wealth Management Inc.現在擁有該公司 1,500 股股票，價值 31,000 美元，此前在上個季度又購買了 600 股。Ball &amp; Co Wealth Management Inc.在第一季度購買了 Summit Therapeutics 的新頭寸，價值約 28,000 美元。Kestra Advisory Services LLC 在第四季度購買了 Summit Therapeutics 的新頭寸，價值約 28,000 美元。Parallel Advisors LLC 在第三季度購買了 Summit Therapeutics 的新頭寸，價值約 39,000 美元。最後，T. Rowe Price Investment Management Inc.在第四季度將其在 Summit Therapeutics 的股份增加了 2,654.4%。T. Rowe Price Investment Management Inc.現在擁有該公司 1,873 股股票，價值 33,000 美元，此前在上個季度又購買了 1,805 股。4.61% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>About Summit Therapeutics</h2>
<div class="lb-trans"><h2>關於 Summit Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Summit Therapeutics plc is a clinical‐stage biotechnology company dedicated to the discovery and development of precision medicines for serious and life‐threatening diseases. The company applies a targeted approach to drug design, focusing on novel mechanisms of action that differentiate its candidates from existing therapies.</p>
<div class="lb-trans"><p>Summit Therapeutics plc 是一家臨牀階段的生物技術公司，致力於發現和開發針對嚴重和危及生命疾病的精準藥物。該公司採用針對性的藥物設計方法，專注於與現有療法不同的新機制。</p>
</div><p>Summit's lead asset, ridinilazole (formerly SMT19969), is being developed to treat Clostridioides difficile infections and has received both Fast Track and Qualified Infectious Disease Product designations from the U.S.</p>
<div class="lb-trans"><p>Summit 的主要資產，ridinilazole（前稱 SMT19969），正在開發用於治療艱難梭狀芽孢桿菌感染，並已獲得美國的快速通道和合格感染性疾病產品的認證。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Summit Therapeutics</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 Summit Therapeutics</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U01NVA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=SMMT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Summit Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Summit Therapeutics 嗎？</h2>
</div><p>Before you consider Summit Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Summit Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Summit Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Summit Therapeutics 並不在名單上。</p>
</div><p>While Summit Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Summit Therapeutics 目前在分析師中獲得 “適度買入” 評級，但頂級分析師認為這五隻股票更值得投資。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Summit Therapeutics (NASDAQ:SMMT) Raised to "Sell" at Wall Street Zen

Market Beat

Summit 治療公司（納斯達克股票代碼：SMMT）在華爾街 Zen 被上調至 “賣出” 評級